Relevant bibliographies by topics / Seconde neoplasie

Academic literature on the topic 'Seconde neoplasie'

Author: Grafiati
Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Seconde neoplasie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Seconde neoplasie"

1

Cantley, Richard L. "Fine-Needle Aspiration Cytology of Cellular Basaloid Neoplasms of the Salivary Gland." Archives of Pathology & Laboratory Medicine 143, no. 11 (September 11, 2019): 1338–45. http://dx.doi.org/10.5858/arpa.2019-0327-ra.

Full text
Abstract:
Context.— Cellular basaloid neoplasms of the salivary gland represent a diverse group of benign and malignant neoplasms with significant cytomorphologic overlap on fine-needle aspiration cytology. All are marked by the presence of monotonous and usually bland basaloid epithelium. Distinction between basaloid neoplasms on fine-needle aspiration cytology is based on the presence or absence of additional features, including a second cell population (eg, myoepithelial cells), an acellular stromal component, and/or cytologic atypia within the basaloid epithelium. This review highlights the cytomorphologic features of the most common cellular basaloid neoplasms of the salivary gland, with an emphasis on classification and subclassification within the Milan System. Objective.— To provide a comprehensive review of the cytologic features of basaloid epithelial neoplasms of the salivary gland, with an emphasis on classification within the Milan System for Reporting Salivary Gland Cytopathology. Data Sources.— Peer-reviewed literature, recent textbooks, and personal experiences of the author. Conclusions.— Some basaloid neoplasms, in particular pleomorphic adenomas and adenoid cystic carcinomas, may have characteristic findings on fine-needle aspiration that allow for definitive diagnosis. In other cases, however, fine-needle aspiration can confirm a neoplastic basaloid process, but specific classification of a benign or malignant neoplasm cannot be rendered. The Milan System for Reporting Salivary Gland Cytopathology acknowledges this difficulty, and recommends benign or malignant classification only when definitive diagnostic features of a specific neoplasm are present. For indeterminate cases, the subcategorization of salivary neoplasm of uncertain malignant potential is recommended.
APA, Harvard, Vancouver, ISO, and other styles
2

Baum, Berit. "Not Just Uterine Adenocarcinoma—Neoplastic and Non-Neoplastic Masses in Domestic Pet Rabbits (Oryctolagus cuniculus): A Review." Veterinary Pathology 58, no. 5 (April 20, 2021): 890–900. http://dx.doi.org/10.1177/03009858211002190.

Full text
Abstract:
With increasing numbers of pet rabbits living out their natural lifespan, rabbit oncology is stepping more and more into the limelight. On the other hand, rabbit tumors are less covered in recent editions of textbooks of veterinary pathology than before. We present 1238 cases with neoplastic and non-neoplastic masses in rabbit tissue, submitted from 2008 to 2019, supplemented by a review of the literature on neoplasms in rabbits. Cutaneous masses comprised 47% of submissions. Trichoblastoma was by far the most common skin neoplasm, and nodular suppurative panniculitis was the second most frequent skin nodule in this series. Epithelial as well as mesenchymal cutaneous neoplasms can be virally induced in rabbits (eg, Shope papilloma, myxomatosis) but were infrequent in the current cases. Mammary neoplasms comprised 21% of submitted masses and 94% of these had histologic features of malignancy. Tumors of the female reproductive tract were responsible for 9% of biopsies and were predominantly uterine adenocarcinoma. Polypoid proliferation of rectal mucosa was the most common lesion in the alimentary tract. A broad spectrum of other neoplasms was described, including sarcomas at vaccination sites and ocular posttraumatic sarcomas, comparable to lesions described in cats.
APA, Harvard, Vancouver, ISO, and other styles
3

de Moura, Joel Pereira, Sérgio Mancini Nicolau, João Norberto Stávale, Maria Aparecida da Silva Pinhal, Leandro Luongo de Matos, Edmund Chada Baracat, and Geraldo Rodrigues de Lima. "Heparanase-2 Expression in Normal Ovarian Epithelium and in Benign and Malignant Ovarian Tumors." International Journal of Gynecologic Cancer 19, no. 9 (November 2009): 1494–500. http://dx.doi.org/10.1111/igc.0b013e3181a834a2.

Full text
Abstract:
Introduction:Studies have highlighted the changes that take place in the environment between the cell and the extracellular matrix during the process of neoplastic expansion. Several papers have associated the expression of heparanase 1 with various malignant tumors. Heparanase 2 is probably related to loss of cell adhesion.Objective:The aim of this study was to evaluate the expression of heparanase 2 in epithelial neoplasia of the ovaries and in samples of normal ovarian tissue.Methods:Seventy-five ovary specimens were analyzed and divided into 3 groups: 23 malignant and 35 benign epithelial ovarian neoplasia and 17 without ovarian disease. We used 2 methodological techniques for evaluating the immunoexpression of heparanase 2. The first followed the qualitative criterion of positive or negative in relation to enzymatic expression, and the second involved computerized quantification of this expression, performed on the same slides.Results:In the quantitative analysis, we found positivity indices for heparanase 2 expression of 72.2% and 87.3% in the samples of benign and malignant neoplasias, respectively. In these, the intensity of expression and the expression index were 147.2 and 121.2, respectively, for the benign neoplasia and 134.1 and 118.0 for the malignant neoplasia. Qualitatively, its expression was strong or moderate in 44.2% of the benign and 78.2% of the malignant tumors; its expression in all of the nonneoplastic samples was negative, with the exception of one that was weakly positive.Conclusions:Heparanase 2 is involved in neoplastic proliferation, but it was not exclusively associated with the malignant process. Furthermore, there was no difference in its expression between benign and malignant ovarian epithelial neoplasia.
APA, Harvard, Vancouver, ISO, and other styles
4

Lesnic, Evelina, and Alina Malic. "Particularities of the evolution of the patients with tuberculosis associated with the pulmonary neoplastic process." Public Health, Economy and Management in Medicine, no. 2(89) (August 2021): 45–50. http://dx.doi.org/10.52556/2587-3873.2021.2(89).08.

Full text
Abstract:
Risk factors for pulmonary tuberculosis and pulmonary neoplastic process are interdependent. Antineoplastic treatment is a contributing factor in the reactivation of latent tuberculosis infection and the recurrence of pulmonary tuberculosis. The aim of the study was to evaluate the particularities of the evolution of patients with tuberculosis associated with pulmonary neoplastic process to identify recommendations for early detection of the neoplastic process. A retrospective, selective study was performed which included 105 patients distributed in the study group that included 50 cases with diagnosed pulmonary neoplatic process and the comparison group which consisted from 65 patients with pulmonary tuberculosis without current or previous neoplasia. Th e peculiarities of patients with associated neoplastic process was age over 55 years, urban residence, incomplete level of education, disadvantaged socio-economic peculiarities, immunosuppressive treatment (in one third of cases). Th e diagnosis of tuberculosis was established by the specialist, having a low rate of positive microbiological status and a wide range of clinical manifestations. Standardized antituberculosis treatment resulted in a low rate of therapeutic success. Conclusion: the standardized management of patients with pulmonary tuberculosis associated with the pulmonary neoplastic process led to the late detection of the neoplastic process and the completion of antituberculosis treatment with therapeutic success only in every second patient.
APA, Harvard, Vancouver, ISO, and other styles
5

Fatima, Rasheed, Sandhya M., and Sowmya T. S. "Study of histomorphological pattern of ovarian neoplastic and non-neoplastic lesions." International Journal of Research in Medical Sciences 5, no. 5 (April 26, 2017): 2095. http://dx.doi.org/10.18203/2320-6012.ijrms20171849.

Full text
Abstract:
Background: The ovary is a striking exception to the Virchow’s dictum that organs that are frequently the site of primary cancer are rarely involved in secondary malignancy, and vice versa. Both primary and secondary carcinomas of the ovary are relatively frequent and show an astounding variety of pathologic patterns. The objectives were to study the histomorphological diversity of various neoplasms and non neoplastic lesions of ovary. To provide a specific diagnosis based upon the histomorphological study which is of paramount clinical significance in further management of the patient.Methods: The present study is based on histomorphological evaluation of 100 cases of ovarian neoplastic and non neoplastic lesions received at the department of Pathology, tertiary care hospital from June 2008 to Aug 2010.Results: A wide variation of age was noted. Among neoplastic lesions, majority of the cases were seen in age group of 20-39 years i.e., 50.6%. Non neoplastic lesion occurred in all age group, but majority of the incidences were seen in the age group of 20 to 40 years of age, accounting for 60% of total occurrence. the commonest ovarian tumor was serous cyst adenoma constituting 54.1% (46 cases) of all ovarian neoplasm. Mucinous cyst adenoma was the second most common tumor. There were 72 cases (85%) of benign, 2 cases (2%) of borderline and 11 cases (13%) of malignant tumors in the present study.Conclusions: The diversity of neoplasms makes it mandatory to classify the tumors accurately by histopathological features following universally accepted classification.
APA, Harvard, Vancouver, ISO, and other styles
6

González, Iván A., Douglas R. Stewart, Kris Ann P. Schultz, Amanda P. Field, D. Ashley Hill, and Louis P. Dehner. "DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma." Modern Pathology 35, no. 1 (October 1, 2021): 4–22. http://dx.doi.org/10.1038/s41379-021-00905-8.

Full text
Abstract:
AbstractDICER1 syndrome (OMIM 606241, 601200) is a rare autosomal dominant familial tumor predisposition disorder with a heterozygous DICER1 germline mutation. The most common tumor seen clinically is the pleuropulmonary blastoma (PPB), a lung neoplasm of early childhood which is classified on its morphologic features into four types (IR, I, II and III) with tumor progression over time within the first 4–5 years of life from the prognostically favorable cystic type I to the unfavorable solid type III. Following the initial report of PPB, its association with other cystic neoplasms was demonstrated in family studies. The detection of the germline mutation in DICER1 provided the opportunity to identify and continue to recognize a number seemingly unrelated extrapulmonary neoplasms: Sertoli-Leydig cell tumor, gynandroblastoma, embryonal rhabdomyosarcomas of the cervix and other sites, multinodular goiter, differentiated and poorly differentiated thyroid carcinoma, cervical-thyroid teratoma, cystic nephroma-anaplastic sarcoma of kidney, nasal chondromesenchymal hamartoma, intestinal juvenile-like hamartomatous polyp, ciliary body medulloepithelioma, pituitary blastoma, pineoblastoma, primary central nervous system sarcoma, embryonal tumor with multilayered rosettes-like cerebellar tumor, PPB-like peritoneal sarcoma, DICER1-associated presacral malignant teratoid neoplasm and other non-neoplastic associations. Each of these neoplasms is characterized by a second somatic mutation in DICER1. In this review, we have summarized the salient clinicopathologic aspects of these tumors whose histopathologic features have several overlapping morphologic attributes particularly the primitive mesenchyme often with rhabdomyoblastic and chondroid differentiation and an uncommitted spindle cell pattern. Several of these tumors have an initial cystic stage from which there is progression to a high grade, complex patterned neoplasm. These pathologic findings in the appropriate clinical setting should serve to alert the pathologist to the possibility of a DICER1-associated neoplasm and initiate appropriate testing on the neoplasm and to alert the clinician about the concern for a DICER1 mutation.
APA, Harvard, Vancouver, ISO, and other styles
7

Charak, Annu, Irfan Ahmed, Bushra Rashid Sahaf, Rehana Qadir, and A. R. Rather. "Clinico-pathological spectrum of testicular and paratesticular lesions: a retrospective study." International Journal of Research in Medical Sciences 6, no. 9 (August 25, 2018): 3120. http://dx.doi.org/10.18203/2320-6012.ijrms20183656.

Full text
Abstract:
Background: Both neoplastic and non neoplastic conditions affect the testis. Although non neoplastic testicular lesions are more common, still most of the studies were done on testicular neoplasms only. Hence the present study was undertaken to study histopathological spectrum of testicular and paratesticular lesions, their age distribution and clinical presentation.Methods: This is a retrospective study of 77 cases of orchidectomy specimens, testicular biopsies and paratesticular lesions received in the department from Jan 2015 to June 2018.Results: Non neoplastic testicular lesions were more common than neoplastic (90.1% Vs 9.8%) with majority in the second and third decade. Undescended testis comprised 46.1% of the total orchidectomy specimens followed by Torsion/Infarction testis (15.3%). None of the undescended testis showed tumour unlike western countries. Majority of patients presented with empty scrotum (31.16%) and testicular/scrotal swelling (18.11%). Only 5 cases of testicular neoplasm were diagnosed during the study period amounting to only 1.42 cases per year. All were germ cell tumours (4 classic seminoma and 1 yolk sac tumour).Conclusions: Non neoplastic testicular lesions were more common than neoplastic lesions. Complete neonatal examination for testicular descent should be mandatory to avoid late presentations and future malignancies. Germ cell tumours formed the bulk of testicular tumours.
APA, Harvard, Vancouver, ISO, and other styles
8

Escobar, P. F., R. Patrick, L. Rybicki, N. Al-Husaini, C. M. Michener, and J. P. Crowe. "Primary gynecological neoplasms and clinical outcomes in patients diagnosed with breast carcinoma." International Journal of Gynecologic Cancer 16, Suppl 1 (January 2006): 118–22. http://dx.doi.org/10.1136/ijgc-00009577-200602001-00019.

Full text
Abstract:
The purpose of this study was to quantify and describe nonmammary neoplasms (n-MN), particularly gynecological neoplasms, in a patient population previously diagnosed with breast cancer. Data were collected prospectively in our institutional review board–approved registry for patients diagnosed with infiltrating breast cancer or ductal carcinoma in situ. Patients who developed a second, n-MN were identified; neoplastic site, time to development after breast cancer, and clinical outcomes were recorded. FIGO stage was recorded for patients who developed a gynecological neoplasm. Synchronous bilateral breast cancer was defined as a second, contralateral diagnosis made within 12 months of the first and, similarly, synchronous n-MN were defined as those identified within 1 year of a breast cancer diagnosis. Outcome curves were generated using the method of Kaplan and Meier, and compared using the log-rank test. Of 4126 patients diagnosed with breast cancer, 3% developed a n-MN, the majority of which were nongynecological and asynchronous to the initial breast cancer diagnosis. Three percent of patients diagnosed with breast cancer were diagnosed with a second, n-MN. Among patients who developed a n-MN, most developed a nongynecological cancer more than 1 year after the initial breast cancer diagnosis, and their outcomes were significantly worse than those patients who did not develop a n-MN.
APA, Harvard, Vancouver, ISO, and other styles
9

Bokemeyer, C., and H. J. Schmoll. "Secondary neoplasms following treatment of malignant germ cell tumors." Journal of Clinical Oncology 11, no. 9 (September 1993): 1703–9. http://dx.doi.org/10.1200/jco.1993.11.9.1703.

Full text
Abstract:
PURPOSE The current study investigates the frequency and outcome of secondary malignancies in patients treated for testicular cancer at Hannover University Medical School between 1970 and 1990. PATIENTS AND METHODS One thousand twenty-five patients with a median follow-up duration of 61 months (range, 12 to 240) were included in the analysis. Follow-up was complete in 1,018 patients (99%). Histology was seminoma in 324 patients (38.7%) and nonseminomatous germ cell tumor in 624 patients (61.3%). At the time of median follow-up, 814 patients (79.9%) were alive. RESULTS Fourteen patients developed a secondary neoplasm (cumulative incidence, 1.38%; 95% confidence interval [CI], 0.75 to 2.30); 13 patients had solid tumors and one had secondary lymphoblastic leukemia with a t(4; 11) translocation including band 11q23. None of 224 patients on surveillance strategy (with or without retroperitoneal lymph node dissection [RPLND]) developed a second neoplasm, compared with four of 413 patients (0.97%; 95% CI, 0 to 1.9) after cisplatin-based chemotherapy (not significant) and nine of 332 patients (2.7%; 95% CI, 0.9 to 4.5) after radiotherapy (P = .02). The cumulative incidence of a secondary neoplasia of 1.76% (95% CI, 0.97 to 2.94) in patients treated by radiotherapy and/or chemotherapy was significantly higher compared with patients on surveillance protocols (P = .03). Chemotherapy containing standard-dose etoposide did not increase the risk of occurrence of secondary neoplasms. A significantly elevated relative risk of 7.53 (range, 3.4 to 14.3) compared with the male German population was only found for patients treated by radiotherapy. CONCLUSION Compared with patients who have other curable malignant tumors, an incidence of 1.38 of secondary neoplasms after a median follow-up duration of 61 months is low. The highest risk for secondary neoplasia after treatment of testicular cancer is associated with the use of radiotherapy. Following chemotherapy, no significantly elevated risk was observed. In conclusion, the benefits of curative treatment far outweigh the risk of secondary cancer in patients with malignant germ cell tumors.
APA, Harvard, Vancouver, ISO, and other styles
10

Torres, L. N., J. M. Matera, C. H. Vasconcellos, J. L. Avanzo, F. J. Hernandez-Blazquez, and M. L. Z. Dagli. "Expression of Connexins 26 and 43 in Canine Hyperplastic and Neoplastic Mammary Glands." Veterinary Pathology 42, no. 5 (September 2005): 633–41. http://dx.doi.org/10.1354/vp.42-5-633.

Full text
Abstract:
Gap junctions are the only communicating junctions found in animal tissues and are composed of proteins known as connexins. Alterations in connexin expression have been associated with oncogenesis; reported studies in rodent and human mammary glands, which normally express connexins 26 and 43, confirm these alterations in malignancies. Mammary neoplasms represent the second most frequent neoplasm in dogs, and since there are no reports on the study of connexins in canine mammary glands, the present study investigated the expression of connexins 26 and 43 in normal, hyperplastic, and neoplastic mammary glands of this species, to verify if altered patterns of connexin staining are related to higher cell proliferation and malignant phenotypes. A total of 4 normal, 8 hyperplastic mammary glands, 9 benign, and 51 malignant mammary gland neoplasms were submitted for the immunostaining of connexins 26 and 43, E-cadherin, and proliferating cell nuclear antigen (PCNA). Normal, hyperplastic, and benign neoplastic mammary glands showed a punctate pattern for connexin 26 and 43 staining and an intercellular E-cadherin staining. Malignant neoplasms, especially the most aggressive cases with high cell proliferation rates, presented either fewer gap junction spots on the cell membranes or increased cytoplasmic immunostaining. Malignant tumors also expressed a less intense immunostaining of E-cadherin; the expression of this adhesion molecule is important for the transportation of connexins to cell membranes and in forming communicating gap junctions. Deficient expression of E-cadherin could be related to the aberrant connexin localization and may contribute to the malignant phenotype. In conclusion, the expression and distribution of connexins and E-cadherin are inversely correlated to cell proliferation in malignant mammary neoplasms of dogs and may well be related to their more aggressive histologic type and biologic behavior.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Seconde neoplasie"

1

Ricci, Marcos Desiderio. "Impacto da mamoplastia redutora contralateral, em pacientes com câncer de mama, na detecção de carcinoma oculto sincrônico e diminuição no risco de carcinoma metacrônico." Universidade de São Paulo, 2005. http://www.teses.usp.br/teses/disponiveis/5/5139/tde-20092010-180741/.

Full text
Abstract:
INTRODUÇÃO: O principal fator de risco para câncer de mama é o antecedente pessoal de câncer na mama contralateral. A mamoplastia redutora de finalidade estética, tem sido implicada com redução no risco para câncer de mama. A mamoplastia redutora contralateral de simetrização, em pacientes operadas por câncer, contribui no diagnóstico de lesões precursoras e carcinoma oculto. OBJETIVOS: Determinar a ocorrência de lesões precursoras e carcinoma oculto de mama, em pacientes submetidas a mamoplastia redutora de simetrização. Comparar estas pacientes, com um grupo controle de pacientes não submetidas a tal cirurgia, analisando o tempo de início da terapia adjuvante quimioterapia ou radioterapia -, tempo livre de doença e sobrevida total, taxa de ocorrência e fatores relacionados com o câncer metacrônico. MÉTODOS: Estudaram-se 249 mulheres com diagnóstico de carcinoma invasivo de mama não metastático, divididas em dois grupos. O grupo estudo, constituído por 114 mulheres submetidas a mamoplastia redutora contralateral, e o grupo controle, constituído por 135 pacientes não submetidas a esta cirurgia. Foram excluídas do estudo todas as pacientes que apresentaram lesões suspeitas na mama oposta, bem como aquelas com antecedente de mamoplastia redutora. RESULTADOS: As pacientes submetidas a mamoplastia redutora de simetrização tiveram diagnóstico de carcinoma invasivo oculto sincrônico em 1,8% dos casos, carcinoma ductal in situ em 2,6%, e lesões proliferativas atípicas em 14,9%. O tempo de início da terapia adjuvante não foi influenciado pela mamoplastia de simetrização (p=0,826). Nas pacientes submetidas a mamoplastia, o câncer contralateral metacrônico ocorreu em 1,8% dos casos, enquanto que no grupo controle em 6,7%, demonstrando indícios de associação entre mamoplastia redutora contralateral e redução na ocorrência de câncer metacrônico (p=0,094). O tempo livre de doença e sobrevida total não foi influenciado pela mamoplastia. Os fatores relacionados com maior ocorrência foram os antecedentes familiares e o diagnóstico do tumor contralateral em estádio inicial. A quimioterapia adjuvante esteve relacionada com diminuição da ocorrência. CONCLUSÕES: A mamoplastia redutora contralateral de simetrização oferece uma oportunidade de diagnóstico de lesões de risco, tumores in situ e invasivos, além de demonstrar indícios de redução da ocorrência de câncer metacrônico durante seguimento oncológico.
INTRODUCTION: The principal risk factor for breast cancer is a personal antecedent of contralateral breast cancer. A reduction mammoplasty has an esthetical purpose and implies in the reduction of the risk of breast cancer. The contralateral and reduction mammoplasty with simetrization in patients with cancer and submitted to surgeries, contributes for the diagnosis of precursor lesions and occult carcinoma. OBJECTIVES: Determine the occurrence of precursor lesions and breast occult carcinoma in patients submitted to reduction mammoplasty with simetrization. Compare these patients with a control group of patients that were not submitted to that type of surgery, analyzing the time of initiating of the adjuvant therapy (chemotherapy and radiotherapy), disease-free time and total survival, occurrence tax and factors related with metachronic cancer. METHODS: 249 women with diagnosis of non-metastatic invasive breast carcinoma were studied and divided in two groups. The studied group was constituted of 114 women, who were submitted to reduction and contralateral mammoplasty, and the control group constituted of 135 patients, who were not submitted to this type of surgery. All the patients suspected to have lesions on the contralateral breast were excluded from this study, as well as, those with antecedents of reduction mammoplasty. RESULTS: The patients submitted to reduction mammoplasty with simetrization had a diagnosis of an occult, synchronic and invasive carcinoma in 1.8% of the cases, ductal carcinoma in situ in 2.6%, and proliferative and atypical lesions were found in 14.9%. The time of initiating the adjuvant therapy had no influence with the mammoplasty of simetrization (p=0.826). Patients submitted to mammoplasty, metachronic contralateral cancer occurred in 1.8% of the cases, whereas the control group demonstrated in 6.7% evidencing association between contralateral and reduction mammoplasty of occurrence of metachronic cancer (p=0.094). The disease-free time of the disease and total survival was not influenced by the mammoplasty. The factors related with a greater occurrence were the familiar antecedents and the diagnosis of the contralateral tumor in initial stage. The adjuvant chemotherapy adjuvant was related with the reduction of the occurrence. CONCLUSIONS: The contralateral and reduction mammoplasty with simetrization gives an opportunity for diagnosis of risk lesions, in situ and invasive tumors, besides demonstrating evidences of reduction of metachronic cancer during the oncological follow-up.
APA, Harvard, Vancouver, ISO, and other styles
2

Prochazka, Michaela. "The risk of second primary lung carcinoma in breast cancer patients /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-649-2/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pinto, Jorge Luiz Freire. "DNA plasmático e urinário em pacientes com câncer de mama - possibilidade de um novo marcador de instabilidade genética tumoral induzida por quimioterapia." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5167/tde-05032010-115349/.

Full text
Abstract:
O câncer de mama é a neoplasia com maior mortalidade entre as mulheres. O emprego de agentes alquilantes no tratamento desta neoplasia pode ocasionar o surgimento de instabilidades genômicas. Tais instabilidades podem estar associadas ao desenvolvimento de neoplasias secundárias como, por exemplo, leucemias. A presente tese avaliou a instabilidade de microssatélites em amostras de sangue, sedimento urinário e plasma de pacientes portadoras de carcinoma mamário ao diagnóstico, 3 e 6 meses após o início do tratamento quimioterápico. Também foi avaliada a concentração do DNA plasmático livre como possível marcador tumoral junto aos marcadores séricos CEA e CA15.3, empregados no acompanhamento do câncer de mama. Foram avaliadas as regiões de microssatélites: Tp53-ALU, Tp53.PCR15.1, BAT 40, BAT26, FMR2 e APC. Entre as 40 pacientes incluídas no presente estudo 88,57% apresentaram instabilidade de microssatélites na fração mononuclear do sangue periférico, 85,8% nas amostras de sedimento urinário e 62,5% no DNA plasmático livre. Não houve concordância significativa entre as instabilidades encontradas nos três tipos de amostra. A concentração de DNA plasmático livre das pacientes quando comparada às doadoras sadias apresentou correlação estatisticamente significativa (p>0,0001), e em paciente em regimes neoadjuvantes que responderam objetivamente à quimioterapia (p=0,02) e não houve correlação com os marcadores séricos CEA e CA15.3.
Breast cancer has the major mortality in women among all kind of cancer. The use of alkylating agents at the treatment of this disease is associated with genomic instability. This instability could be associated with the development of secondary cancer, for example, leukemia. The present thesis evaluated microsatellite instability in blood, pellet cells urinary and plasma in patients with breast cancer at diagnosis, 3 and 6 months after the beginning of chemotherapy. There were evaluated also Free Plasmatic DNA concentration as a possible tumoral marker with the serum markers CEA and CA15.3 used in breast cancer follow up. The microsatellites regions assayed were: Tp53-ALU,Tp53.PCR15.1, BAT 40, BAT26, FMR2 e APC. Among the 40 patients included at the present study 88,57% showed microsallite instability in peripheral mononuclear blood cells, 85,8% in urinary pellet cells samples and 62,5% in Free Plasmatic DNA. There werent statistical significant relationship for the instability found at the three kind of samples assayed. The Free Plasmatic DNA concentration of the patients when compared with healthy donors, showed a statistical significant relationship (p<0,0001). And among patients in neoadjuvant chemotherapy regime who reacted positively by treatment (p=0,02). And there werent statistical significant relationship between Free Plasmatic DNA and serum markers CEA and CA15.3.
APA, Harvard, Vancouver, ISO, and other styles
4

Kleinerman, Ruth. "Second cancers following treatment for retinoblastoma." Thesis, City, University of London, 2016. http://openaccess.city.ac.uk/17330/.

Full text
Abstract:
Improvements in treatment over the past century have greatly increased survival for retinoblastoma, a rare childhood tumour of the eye, caused by mutations of the RB1 tumour suppressor gene. However, as survival for retinoblastoma has improved, those with the hereditary form of the disease (RB1 germline mutation) have elevated risks of developing additional cancers, mostly bone and soft tissue sarcomas and melanoma. Despite advances in understanding of second cancer risks following treatment for retinoblastoma, key research questions remained including 1) risks of common adult onset cancers, some of which have somatic mutations in the RB1 pathway and are associated with ionizing radiation; 2) persistence of increased risks of bone and soft tissue sarcomas into adulthood; 3) clarification of risks of second cancers following chemotherapy to treat retinoblastoma and 4) role of genetic susceptibility to second cancers following retinoblastoma. In response to these questions, a large cohort of 1852 long-term survivors of retinoblastoma was assembled to evaluate systematically the risk of second cancers. The work described in this thesis, which comprises six major studies, that have used this cohort to identify a higher risk than previously assumed of lung cancer; confirmed the increased risk of second cancers in survivors with a RB1 germline mutation and past radiotherapy; documented for the first time that risk of soft tissue sarcomas varied by subtype; demonstrated that mortality from second cancers exceeded that from retinoblastoma; provided new information on variation in second cancer risk by family history of retinoblastoma; and clarified that chemotherapy in addition to radiotherapy for retinoblastoma confers a higher risk for second cancers compared with radiotherapy alone. These studies collectively have provided risk data that can be used to inform survivors and their health care providers to facilitate screening or surveillance and early identification of second cancers.
APA, Harvard, Vancouver, ISO, and other styles
5

Wilson, Carmen Louise Children's Cancer Institute Australia for Medical Research UNSW. "The late effects of therapy in an Australian cohort of childhood cancer survivors." Awarded By:University of New South Wales. Children's Cancer Institute Australia for Medical Research, 2008. http://handle.unsw.edu.au/1959.4/43794.

Full text
Abstract:
In Australia, up to 80% of individuals diagnosed with childhood cancer are now expected to survive for more than five years after their initial diagnosis. However, survivors of childhood cancer are at risk of developing late sequelae as a consequence of therapies received during childhood. The aim of this study was to determine the incidence of selected late sequelae in a cohort of Australian childhood cancer survivors and identify treatment and genetic factors that may modify the risk of late sequelae in survivors. Our study included 1150 individuals treated for childhood cancer at the Sydney Children??s Hospital between 1962 and 1999, who had remained in remission >3 years and were confirmed to be alive. Rates of mortality and second cancers among survivors were compared against population rates to determine standardised mortality and incidence ratios. Survivors completed a questionnaire on the incidence of adverse health conditions and provided a buccal specimen. Real time PCR was used to detect polymorphisms in genes involved in drug detoxification and transport. Rates of mortality and secondary cancers were found to be 7.5-fold (95%CI 5.4-10.1) and 4.9-fold (95%CI 2.9-8.0) higher among survivors of childhood cancer relative to the general population, respectively, with the highest risks observed for those survivors previously treated for Hodgkin??s disease. Over 60% of survivors reported at least one cardiopulmonary, endocrine or sensory-motor condition following diagnosis of childhood cancer; the most frequently observed conditions included growth hormone deficiency, hypothyroidism, and hypertension. Late sequelae were most frequently reported by females and survivors of brain tumours. Genetic investigations showed that an increased risk of growth hormone deficiency was associated with homozygosity for the GSTM1 null polymorphism, while no gene associations were observed to influence the risk of second cancers among survivors. Our study demonstrates that survivors of childhood cancer are at risk of developing a variety of health conditions as a result of anti-cancer therapies received during childhood. Determining risk factors for late sequelae based on therapy type, lifestyle and genetic predisposition will enable the optimisation of treatment protocols and promote the future well-being of childhood cancer survivors.
APA, Harvard, Vancouver, ISO, and other styles
6

Bongiovanni, Alberto <1981&gt. "Predictive And Prognostic Role Of Biological Markers In Neuroendocrine Neoplasia And Evaluation Of Activity And Safety Of Second Line Treatments In Neuroendocrine Carcinoma Patients." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2022. http://amsdottorato.unibo.it/9994/1/text%20PHD%20post%20rev_merged.pdf.

Full text
Abstract:
BACKGROUND Neuroendocrine neoplasia (NEN) are divided in well differentiated G1,G2 and G3 neuroendocrine tumors (NETs) and G3 neuroendocrine carcinomas (NECs). For the latter no standard therapy in second-line is available and prognosis is poor. METHODS Primary aim was to evaluate new prognostic and predictive biomarkers (WP1-3). In WP4 we explored the activity of FOLFIRI and CAPTEM as second-line in NEC patients in a multicenter non-comparative phase II trial RESULTS In WP1-2 we found that 4 of 6 GEP-NEC patients with a negative 68Ga-PET/CT had a loss of expression of RB1. In WP3 on 47 GEP-NENs patients the presence of DLL3 in 76.9% of G3 NEC correlate with RB1-loss (p<0.001), negative 68Ga-PET/CT(p=0.001) and a poor prognosis. In the WP4 we conducted a multicenter non-comparative phase II trial to explore the activity of FOLFIRI or CAPTEM in terms of DCR, PFS and OS given as second-line in NEC patients. From 06/03/2017 to 18/01/2021 53 out of 112 patients were enrolled in 17 of 23 participating centers. Median follow-up was 10.8 (range 1.4 – 38.6) months. The 3-month DCR was 39.3% in the FOLFIRI and 32.0 % in the CAPTEM arm. The 6-months PFS rate was 34.6% ( 95%CI 17.5-52.5) in FOLFIRI and 9.6% (95%CI 1.8-25.7) in CAPTEM group. In the FOLFIRI subgroup the 6-months and 12-months OS rate were 55.4% (95%CI 32.6-73.3) and 30.3% (CI 11.1-52.2) respectively. In CAPTEM arm the 6-months and 12-months OS rate were 57.2% (95%34.9-74.3) and 29.0% (95%10.0-43.3). The miRNA analysis of 20 patients compared with 20 healthy subjects shows an overexpression of miRNAs involved in staminality , neo-angiogenesis and mitochontrial anaerobic glycolysis activation. CONCLUSION WP1-3 support the hypothesis that G3NECs carrying RB1 loss is associated with a DLL3 expression highlighting a potential therapeutic opportunity. Our study unfortunately didn’t met the primary end–point but the results are promising
APA, Harvard, Vancouver, ISO, and other styles
7

Hartman, Mikael. "Risk and prognosis of breast cancer among women at high risk of the disease /." Stockholm : Karolinska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-303-0/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tanizawa, Roberta Sandra da Silva. "Estudo morfológico e por citogenética da medula óssea de portadores de síndrome mielodisplásica secundária no Serviço de Hematologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo." Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5167/tde-27092010-145739/.

Full text
Abstract:
As Síndromes mielodisplásicas (SMD) são doenças clonais da célula progenitora hematopoética, cursando com citopenias, medula óssea displástica e tendência à evolução para leucemia. As SMD secundárias estão associadas a fatores de risco como doenças congênitas (Anemia de Fanconi), doenças hematológicas adquiridas (aplasia medular, HPN), exposição à quimioterápicos (alquilantes, inibidores de topoisomerase II) e radioterapia e substâncias químicas (benzeno, petróleo). Agentes imunossupressores associados ou não a fatores hemopoéticos particularmente utilizados para tratamento da Aplasia medular também se associam à SMD secundária. A OMS recentemente adotou o termo síndrome mielodisplásica/neoplasia mielóde (SMD/NM) relacionada à terapêutica para englobar casos de neoplasias mielóides que preencham critérios morfológicos não somente de SMD, mas também de leucemia mielóide aguda (LMA) ou neoplasias mieloproliferativas. O objetivo do trabalho foi analisar dados clínicos, morfológicos e citogenéticos de 42 portadores de SMD/NM secundária em uma coorte de pacientes diagnosticados no SH-HCFMUSP no período de 1987 a 2008. Vinte e três pacientes (54,8%) eram homens, com mediana de idade de 53,5 (4-88) anos. 45,2% eram portadores de doenças onco-hematológicas, 26,2% de anemia aplástica, 14,3% de tumores sólidos e 14,3% de outras doenças (auto-imunes e transplante de órgãos sólidos). 33% dos pacientes utilizaram exclusivamente QT, 26% combinação QT e RT, 2% RT isolada e 28% agentes imunossupressores. Cinco (11,9%) pacientes haviam sido submetidos a TCTH autólogo para tratamento de doença oncohematológica prévia. A mediana da latência entre a doença primária e a SMD secundária foi de 85 meses (23- 221 meses). Oito pacientes foram submetidos ao TCTH alogênico aparentado para tratamento da SMD secundária. Anemia, neutropenia, plaquetopenia e blastos circulantes foram observados em 64,3%, 54,8%, 78,6% e 26,2% dos casos respectivamente. Cerca de 1/3 dos aspirados medulares apresentavam hemodiluição, 29,7% apresentavam hipocelularidade global, 62,2% apresentavam contagem de blastos superior a 5% e 14,3% sideroblastos em anel acima de 15%. Displasia da série eritróide, granulocítica e megacariocítica foi observada em 79,4%, 77,1% e 68,2% dos casos respectivamente. A histologia medular realizada em 22 casos revelou hipocelularidade global, ALIPs e nódulos linfóides em 9,1%, 23,8% e 40,9% dos casos. A detecção por imunoistoquímica de células CD34>1%, CD117>1%, agrupamento de células CD34+ e de CD117+ e da proteína p53+ foi observada respectivamente em 77,2%, 82,3%, 59%, 29,4% e 33,3% dos casos. Anormalidades clonais foram observadas em 84,3% dos casos, com grande predomínio das não balanceadas (96%), sendo 37% com monossomia 7, 44,4% cariótipos complexos e 18% com outras anormalidades . A mediana de sobrevida de sobrevida global foi de 5,7 meses, pacientes submetidos ao TCTH alogênico para tratamento da SMD/NM secundária tiveram mediana de 40 meses (p=0,007). Fatores associados à pior sobrevida incluíram: doença oncohematológica prévia, baixa contagem plaquetária, elevação de DHL e ferritina, presença de células CD117+ agrupadas, imunoexpressão positiva da p53, citogenética anormal, IPSS intermediário II ou alto risco. Nenhum parâmetro estudado do aspirado medular se associou à sobrevida. Houve tendência à associação da imunoexpressão positiva de p53 a cariótipo anormal e IPSS de maior risco. Não se observou associação entre a presença de ALIP, porcentagem de blastos na morfologia medular e células CD34+ e CD117+. Estes dados reforçam a importância da análise citogenética e da imunoistoquímica da biópsia de medula óssea para diagnóstico e prognóstico das SMD secundárias e do TCTH alogênico no seu tratamento. Mais estudos com maior número de casos devem ser realizados para confirmar a importância do escore IPSS na SMD secundárias, provavelmente substituindo a porcentagem de blastos ao aspirado medular, pela presença de células precursoras detectadas por imunoistoquímica
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders, characterized by cytopenias, dysplastic bone marrow (BM) and propensity to progress to acute myeloid leukemia. Secondary MDS are associated with risk factors such as congenital disorders (Fanconis anemia), acquired bone marrow failures, exposure to chemotherapy (alkylating agents, topoisomerase II inhibitors) agents and radiation and chemicals (benzene, petroleum). Immunosuppressive agents associated with hematopoietic growth factors are also associated with secondary MDS. The WHO classification has recently adopted the term therapy-related myeloid neoplasms for cases of myeloid malignancies that fulfill morphological criteria not only for MDS but also for AML or myeloproliferative neoplasms.The aim of the study was to analyze clinical, morphological and cytogenetic features of 42 patients with secondary MDS/MN in a cohort of patients diagnosed at our institution from 1987 to 2008. 23 patients (54.8%) were male, median age 53.5 (4-88) years. 45.2% had primary hematologic malignancies, 26.2% aplastic anemia, 14.3% solid tumors and 14.3% other diseases (autoimmune diseases and solid organ transplantation). 33% had undergone chemotherapy alone, 2% RT alone, 26% both modalities and 28% immunosuppressive agents. Five (11.9%) patients had undergone autologous HSCT for treatment of previous malignancies. The median latency between the primary disease and secondary MDS/MN was 85 (23-221) months. Eight patients underwent allogeneic HSCT (allo- HSCT) for treatment of related secondary MDS. Anemia, neutropenia, thrombocytopenia and peripheral blasts were observed in 64.3%, 54.8%, 78.6% and 26.2%, respectively. BM aspirates was poorly representative in 1/3 of cases, 29.7% global hypocellularity, 62.2% more than 5% of blast counts and 14.3% more than 15% of ring sideroblasts. Dysplasia in erythroid, granulocytic and megakaryocytic series was observed in 79.4%, 77.1% and 68.2%, respectively. Twenty two BM biopsies were performed. Global hypocellularity, ALIP and lymphoid nodules were shown in 9.1%, 23.8% and 40.9%. The immunohistochemistry showed more than 1% of CD34+ and CD117+ cells, clusters of CD34+ and CD117+ and immunoexpression of p53 protein in 77.2%, 82.3%, 59%, 29.4% and 33.3%, respectively. Clonal abnormalities were observed in 84.3% of cases with high prevalence of unbalanced (96%) rearrangements. 37% showed monosomy 7 and 44.4% complex karyotypes. The median overall survival was 5.7 for all patients and 40 months for patients treated with allo-HSCT (P=0.007). Hematologic malignancies, low platelet count, serum high LDH and ferritin, detection of CD117+ clusters, positive immunoexpression of p53, abnormal cytogenetics, intermediate-II or high-risk IPSS groups were associated with poor survival. No parameter studied from bone marrow aspirate had impact in survival. p53 expression was associated to abnormal karyotype (P=0.092) and IPSS risk (P=0.054). There was no association between the presence of ALIP, BM blast counts and immunoexpression of CD34+ and CD117+. Our study shows that cytogenetic analysis and BM immunohistochemistry are very important in diagnosis and prognosis, and that allo-HSCT could improve the survival of secondary MDS/MN. More studies with larger numbers of cases should be conducted to confirm the importance of the IPSS for secondary MDS, probably replacing the bone marrow aspirate blast counts by the immunohistochemistry detection of precursor cells
APA, Harvard, Vancouver, ISO, and other styles
9

Birgisson, Helgi. "Cancer of the Colon and Rectum : Population Based Survival Analysis and Study on Adverse Effects of Radiation Therapy for Rectal Cancer." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6824.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pereira, Lucy. "Validation of the 60-second chair rise as a measure of physical function in patients with non-small cell lung cancer." Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=116113.

Full text
Abstract:
Yearly, 22, 200 Canadians are diagnosed with lung cancer, with 80-85% of the cases being non-small cell lung cancer (NSCLC). With diagnoses being predominantly in the advanced stages, prognosis is poor and quality of life (QoL) becomes the focus of treatment. The main symptom cachexia, issues a loss of strength and impacts on an important aspect of QoL, physical function. Physical function is predominately assessed subjectively. Lately performance-based measures are gaining in popularity. One performance measure, the chair rise test, has not been validated in the NSCLC population and was the objective of this study.
Subjects completed the chair rise test, 6MWT, hand grip, and the SF-36 pre and post chemotherapy. Evidence for construct and discriminant validity but not predictive validity was provided for the chair rise test. The 60-second chair rise may be too strenuous for persons with severe disability but a standardized timed-based chair rise test is needed.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Seconde neoplasie"

1

T, Galeotti, ed. Cell membranes and cancer: Proceedings of the Second International Workshop on Membranes in Tumour Growth, Rome, Italy, June 17-20, 1985. Amsterdam: Elsevier Science, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Peter, De Wulf, and Earnshaw William C, eds. The kinetochore: From molecular discoveries to cancer therapy. New York: Springer, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Peter, De Wulf, and Earnshaw William C, eds. The kinetochore: From molecular discoveries to cancer therapy. New York: Springer, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

K, Cavenee W., Ponder, B. A. J. 1944-, Solomon E, and Imperial Cancer Research Fund (Great Britain), eds. Genetics and cancer: A second look. Plainview, N.Y: Cold Spring Harbor Laboratory Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

S, Mitchell Malcolm, ed. Immunity to cancer II: Proceedings of the Second Conference on Immunity to Cancer held at Williamburg, Virginia, November 9-11, 1987. New York: Liss, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Julian, Rosenthal C., and Rotman Marvin 1933-, eds. Infusion chemotherapy--irradiation interactions: Principles and applications to organ salvage and prevention of second primary neoplasms. New York: Elsevier, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

McLean, David I., MD, FRCPC. and Williams Dan 1957-, eds. The prevention of second primary cancers: A resource for clinicians and health managers. Basel: Karger, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Second primary cancers and cardiovascular disease after radiation therapy. Bethesda, Md: National Council on Radiation Protection and Measurements, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1944-, Foley Kathleen M., Bonica John J. 1917-, and Ventafridda Vittorio, eds. Proceedings of the Second International Congress on Cancer Pain. New York: Raven Press, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Institute of Medicine (U.S.). Planning Committee on Policy Issues in Nanotechnology and Oncology and National Cancer Policy Forum (U.S.), eds. Nanotechnology and oncology: Workshop summary. Washington,D.C: National Academies Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Seconde neoplasie"

1

Bhatia, Smita. "Second Malignant Neoplasms." In Handbook of Long Term Care of The Childhood Cancer Survivor, 209–20. Boston, MA: Springer US, 2015. http://dx.doi.org/10.1007/978-1-4899-7584-3_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vannucchi, Alessandro M. "Polycythemia Vera and Essential Thrombocythemia: When to Change Therapy – Second-Line Options." In Myeloproliferative Neoplasms, 119–29. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-24989-1_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Russell, Robert T., and Anna T. Meadows. "Organ Dysfunction, Second Malignant Neoplasms, and Survival." In The Surgery of Childhood Tumors, 615–27. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-48590-3_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Paterson, Felicity, Susannah Stanway, Lone Gothard, and Navita Somaiah. "Second Primary Neoplasms Following a Diagnosis of Breast Cancer." In Breast Cancer Survivorship, 213–34. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-41858-2_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kleinerman, Ruth A., Jasmine H. Francis, and David H. Abramson. "Second Primary Neoplasms in Retinoblastoma: Effect of Gene and Environment." In Albert and Jakobiec's Principles and Practice of Ophthalmology, 7941–52. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-42634-7_266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kleinerman, Ruth A., Jasmine H. Francis, and David H. Abramson. "Second Primary Neoplasms in Retinoblastoma: Effect of Gene and Environment." In Albert and Jakobiec's Principles and Practice of Ophthalmology, 1–12. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-319-90495-5_266-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Amsbaugh, Mark J., and Shiao Y. Woo. "Second Neoplasms After Successful Treatment for Pediatric Central Nervous System Tumors." In Radiation Oncology for Pediatric CNS Tumors, 595–624. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-55430-3_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nosé, Vânia, and E. Tessa Hedley-Whyte. "Diseases of the Pituitary Gland." In Escourolle and Poirier's Manual of Basic Neuropathology, 343–64. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199929054.003.0014.

Full text
Abstract:
A wide variety of distinct pathological conditions may affect the pituitary, causing hormonal dysfunction and/or compression of surrounding structures. This chapter describes and illustrates the main pituitary lesions. Pituitary adenomas represent 10% to 20% of intracranial neoplasms in neurosurgical series. Their classifications are based on multiple factors, including histology and immunohistochemistry, ultrastructure and endocrine activity. Pituitary carcinomas are extremely rare. Pituitary hyperplasia is a rare cause of pituitary hyperfunction. Inflammatory (lymphocytic hypophysitis, granulomatous hypophysitis) and vascular (pituitary infarction, pituitary apoplexy, Sheehan syndrome) lesions can cause hypopituitarism. Craniopharyngiomas are the second most common neoplasm of the sellar region, following pituitary adenomas, and the most common suprasellar neoplasm in children.
APA, Harvard, Vancouver, ISO, and other styles
9

Plastaras, John P., Daniel M. Green, and Giulio J. D'Angio. "Second Malignant Neoplasms." In Abeloff's Clinical Oncology, 1023–37. Elsevier, 2008. http://dx.doi.org/10.1016/b978-0-443-06694-8.50070-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Friedman, Debra L. "Second Malignant Neoplasms." In Abeloff's Clinical Oncology, 741–50. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-323-47674-4.00050-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Seconde neoplasie"

1

Farias, Nathália dos Santos, Beatriz Silva Silveira, Isabela Mascarenhas de Andrade, Lara Cordeiro Magalhães, Maria Luísa Sousa Weber, and Maria Clara Cotrim Pereira. "Mortality Rate of CNS neoplasms in childhood in Brazil." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.202.

Full text
Abstract:
Background: The variety of tumors of the Central Nervous System (CNS) during childhood is related to heterogenous clinical manifestations and to an important mortality rate (MR). In Brazil, CNS tumors represent the second most incident cancer during childhood and the main cause of death of children between ages 0-9. Objectives: To describe the number of hospitalizations and the MR of CNS neoplasms by childhood age group in Brazil. Design and Methods: This is a descriptive ecological study based on secondary data, obtained from DATASUS. Data were collected regarding the number of hospitalizations and MR by childhood age group due to neoplasm of the CNS in Brazil between the years 2009-2019. Results: A total of 38192 hospitalizations happened, resulting in 5.91% of MR. The highest value of brain’s neoplasms MR was found in children up to 1 year old (9,34%), but when it comes to number of hospitalizations, the group between ages 5-9 had the highest number, both in neoplasms of the brain (9364) and of other parts of the CNS (1767). Conclusions: The present study pointed out that the childhood age group with the lowest number of hospitalizations (less than 1 year) presented simultaneously the highest MR of CNS tumors.
APA, Harvard, Vancouver, ISO, and other styles
2

Lamonier, L., F. Bottcher-Luiz, L. Pietro, L. A. L. A. Andrade, A. A. de Thomaz, C. L. Machado, and C. L. Cesar. "Second harmonic generation in human ovarian neoplasias." In BiOS, edited by Ammasi Periasamy, Peter T. C. So, and Karsten König. SPIE, 2010. http://dx.doi.org/10.1117/12.842576.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rocha, Ariane Silva da, Maria Paula Curado, and Gisele Aparecida Fernandes. "THIRD AND FOURTH IPSILATERAL AND CONTRALATERAL PRIMARY BREAST CANCER IN A COHORT OF WOMEN TREATED FROM 2000 TO 2015 AT AC CAMARGO CANCER CENTER." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2040.

Full text
Abstract:
This study aims to describe the clinical and pathological characteristics in women with breast cancer with three or four ipsilateral and contralateral malignant tumors. The second primary malignant neoplasm of the breast is a condition in which the frequency of occurrence is around 50%, mainly in young women. The occurrence of the third and fourth neoplasms is rare, between 0.73% and 11.7%. This is a retrospective cohort study of women with breast cancer from 2000 to 2015. We identified 375 women with second primary breast tumor, of which 6 (1.6%) had three and four new primary breast cancer. Of the six cases with three and four neoplasms, three cases occurred in the QIE (lower left quadrant), overlapping lesion in two cases, and two cases in the QSE (upper left quadrant). Zero clinical and pathological staging was observed in two cases, I in two cases, IIA in two cases, and IA in one case, invasive lobular carcinoma in four cases, and invasive ductal carcinoma in three cases. The molecular subtype luminal occurred in four cases, HER2 overexpressed in three cases, estrogen receptor and HER2 were negative in three cases, and progesterone positive in three cases. The time of diagnosis between the first, third, and fourth tumor ranges from 2 to 72 months. Therefore, more studies are needed on the third and fourth malignant breast tumors as it is a rare entity in patients whose genetic and molecular characteristics are poorly known.
APA, Harvard, Vancouver, ISO, and other styles
4

Pâslaru, Ana Maria, Ana Maria Fătu, Alexandru Nechifor, Laura Florentina Rebegea, Diana Bulgaru Iliescu, and Anamaria Ciubara. "PSYCHO-ONCOLOGY. CASE PRESENTATION." In The European Conference of Psychiatry and Mental Health "Galatia". Archiv Euromedica, 2023. http://dx.doi.org/10.35630/2022/12/psy.ro.35.

Full text
Abstract:
Increased survival of oncology patients brings to attention new aspects of adverse effects due to antineoplastic treatment. Psychiatric disorders, cardiovascular disorders as well as the progressive incidence of multiple primary neoplasia are some of the most common side effects. Aim: Care of the oncology patient undergoes an important period of change, from the management of tumor disease to the multidisciplinary approach, centered on improving the quality of life. Method: We present the case of a 75-year-old patient, whose personal pathological history reveals the presence of a diagnosis of left testicular seminoma, in 1978, for which he received radiochemical therapy. An oncological patient under long-term medical supervision for several decades is diagnosed in November 2017 with urothelial carcinoma, infiltrative, invasive in his own muscle patch, pT2NxMx. Approximately 40 years later, the second neoplastic site, the malignant bladder tumor, appears. Facing this diagnosis, the patient becomes anxious, anticipates catastrophic consequences, isolates himself. The family and friends support is essential in these moments, the patient tries cognitive-behavioral psychotherapy, as well as various relaxation techniques, which have positive results for the patient attitude towards the disease. He admits, to complete staging, to follow the recommendations of the oncologist, perform proton emission tomography, which detects the presence of two lesions on the right lung. In January 2018, the surgical intervention is done by straight thoracotomy, atypical upper lobe resection and inferior lobectomy is performed. The histopathological and immunohistochemical results describe the presence of the third primary adenocarcinoma neoplasia. The initial emotional reaction is one of anger, denial, followed by demoralization, easy crying, sadness. The patient is examined by the psychiatrist, thus receiving the diagnosis of a severe depressive episode without psychotic symptoms. He follows an anxiolytic, antidepressant, sedative treatment but continues also the cognitive-behavioral therapy. The patient shows good compliance with psychopharmacological treatment and accepts adjuvant chemotherapy courses, which are well tolerated. Throughout the antineoplastic therapy, there was a close collaboration between the psychiatrist and the oncologist, to avoid drug interactions that could have led to interruption of the treatment. Under the oncology supervision, the patient receives another bad news, in September 2018, the fourth neoplastic localization, the prostatic adenocarcinoma pT2bN0M0, is discovered. In this case, in the presence of the combination of synchronous and methacrone tumors, the patient's psyche is deeply affected, continuing the psychopharmacological treatment. Conclusions: Psychiatric disorders are common among oncological patients, and they may suffer serious impairments in quality of life and treatment compliance, psycho-oncological collaboration being indispensable for the success of antineoplastic treatment.
APA, Harvard, Vancouver, ISO, and other styles
5

Lamiri, Hadir, Hajer Bettaieb, Hadhami Rouiss, Nesrine Souayeh, Meriem Ouederni, Rahma Bouhmida, Amal Chermiti, Hedhili Oueslati, and Chaouki Mbarki. "EP402/#1074 Epidemiology of gestational trophoblastic neoplasia in a second level hospital in Tunisia." In IGCS 2022 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-igcs.491.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sherborne, Amy, Philip Davidson, Katharine Yu, Alice Nakamura, Mamunur Rashid, and Jean Nakamura. "Abstract A50: Mutational analysis of a mouse model of second malignant neoplasms." In Abstracts: AACR Special Conference: Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship; November 9-12, 2015; Fort Lauderdale, Florida. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.pedca15-a50.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Vargas, G., T. Shilagard, Ki-Hong Ho, and S. McCammon. "Multiphoton autofluorescence microscopy and second harmonic generation microscopy of oral epithelial neoplasms." In 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2009. http://dx.doi.org/10.1109/iembs.2009.5332783.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Malev, Carlo C. "Abstract IA15: Measuring evolution in neoplasms." In Abstracts: Second AACR International Conference on Frontiers in Basic Cancer Research--Sep 14-18, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.fbcr11-ia15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zong, Xuchen, Jason D. Pole, Paul Grundy, Salaheddin M. Mahmud, Louise Parker, and Rayjean J. Hung. "Abstract 3713: Second malignant neoplasms after non-CNS embryonal tumors in North America." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tran-Thanh, D., D. Tran-Thanh, N. Arneson, M. Pintilie, K. Warren, A. Bane, F. O'Malley, F. O'Malley, S. Done, and S. Done. "Amplification of the Prolactin Receptor Gene in Mammary Lobular Neoplasia." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-4151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Seconde neoplasie' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography